



February 18, 2020

Re: SECURE-IBD COVID-19 update #21

Dear Colleagues,

We hope this newsletter finds you well and hopefully, vaccinated. The number of COVID-19 cases reported to SECURE-IBD continues to rise. As of February 16, 2021, there have been 5,202 COVID-19 cases in IBD patients reported from 68 countries. With the new variants, the need to vaccinate everyone, including our patients, is even more urgent.


The teams that conducted the two ancillary studies using SECURE-IBD data (1. COVID-19 outcomes in IBD patients in Latin America and 2. The impact of IBD activity on COVID-19 outcomes, including interaction with age) presented their findings earlier this week to the advisory board. We look forward to their publications. We continue to accept applications for ancillary studies on a case by cases basis. Please share this information with interested colleagues, trainees and especially students.

We are also excited to share that all six of our submissions to DDW were accepted for presentation (titles below). We are very grateful to all of you for your ongoing collaboration and for making SECURE-IBD a success.

1. COVID-19 outcomes among racial and ethnic minority individuals with inflammatory bowel diseases in the United States (Poster of Distinction)
2. The first and second wave of COVID-19 in patients with inflammatory bowel disease: a temporal trend analysis (Poster of Distinction)
3. Multivariable prediction models for hospitalization, ventilation, and death from COVID-19 in IBD patients (Poster)
4. the impact of vedolizumab therapy on COVID-19 outcomes in adult IBD patients in the SECURE-IBD registry (Poster)
5. The effects of comorbidities on COVID-19 outcomes among patients with inflammatory bowel disease (Poster)
6. New gastrointestinal symptoms are common in inflammatory bowel disease patients with COVID-19: data from an international registry (Poster)

We have submitted manuscripts on the [COVID-19 Risk Calculator](#), disparities in outcomes by race and ethnicity, impact of comorbid conditions and temporal trends in COVID-19 reporting in SECURE-IBD database. Ongoing studies include those on GI symptoms of COVID-19, outcomes with vedolizumab use and revisiting 5ASA and COVID-19 outcomes.

**Please continue to spread the word about SECURE-IBD to all of your colleagues, locally, nationally, and internationally!**



Interactive web-based map: <http://covidibd.org/map/>

You may download flyers translated into 17 languages at <https://covidibd.org/press/>

### Frequently Asked Questions

**What is SECURE-IBD?** Surveillance Epidemiology of Coronavirus) Under Research Exclusion (SECURE-IBD) is an international, pediatric and adult registry to monitor and report on outcomes of COVID-19 occurring in IBD patients. The registry contains only de-identified data, in accordance with [HIPAA Safe Harbor De-Identification standards](#). The UNC-Chapel Hill Office for Human Research Ethics has determined that storage and analysis of de-identified data does not constitute human subjects research as defined under federal regulations [45 CFR 46.102 and 21 CFR 56.102] and does not require IRB approval.

**How can a provider report a case?** We encourage **all IBD providers to report all cases of confirmed COVID-19** in IBD patients, regardless of severity. Reporting should take at most 5 minutes. Please report only confirmed COVID-19 cases, and report after a minimum of 7 days from COVID diagnosis and sufficient time has passed to observe the disease course through resolution of acute illness or death. **To report a case of coronavirus, click [here](#)**

**Who is organizing this project?** This project is being led by Drs. Michael Kappelman (Pediatric Gastroenterologist) and Erica Brenner (Pediatric Gastroenterology fellow) at the University of North Carolina at Chapel Hill and Dr. Ryan Ungaro (Gastroenterologist), Dr. Manasi Agrawal (Gastroenterologist) and Dr. Jean-Frederic Colombel (Gastroenterologist) at the Icahn School of Medicine at Mount Sinai, New York.

**Are there any partnering organizations/societies?** Official partners include the Crohn's & Colitis Foundation, the International Organization for the Study of IBD (IOIBD), the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN), the European Crohn's and Colitis Organisation (ECCO), the Asian Organization for Crohn's & Colitis, and the Pan American Crohn's and Colitis Organisation (PANCCO). We also acknowledge the promotional support of many local/regional societies and pharmaceutical companies as detailed on [www.covidibd.org](http://www.covidibd.org).



European Crohn's and Colitis Organisation



Please visit us at [www.covidibd.org](http://www.covidibd.org) for updated information or to report a case.

Follow us on Twitter: @SecureIBD

If you have any questions, please reach out to [COVID.IBD@unc.edu](mailto:COVID.IBD@unc.edu).

**Through worldwide collaboration, we can make a large difference!**

**Best,**

**Mike, Erica, Jean-Fred, Ryan and Manasi**

**Advisory Committee Members**

North America: Jim Lewis and Gil Kaplan

Nursing and Advanced Practitioners: Michele Kissous-Hunt

Europe: Walter Reinisch and Jean-Francois Rahier

Asia: Siew Ng

S. America: Flavio Steinwurz

Australia/New Zealand: Richard Gearry

Industry: Irene Modesto

IOIBD: Marischka Konings